Therapy Areas: Oncology
X4 Pharmaceuticals Names Bridger to Board of Directors
8 November 2018 - - Gary J. Bridger, PhD has been elected to teh board of directors of US-based biotechnology company X4 Pharmaceuticals, the company said.

Bridger was a co-founder and chief scientific officer of AnorMED, Inc., through its acquisition by Genzyme in 2007.

Previously, he served as a board member for Alder Biopharmaceuticals, as executive vice president of Research and Development of Xenon Pharmaceuticals, and as managing director at Five Corners Capital. Currently, Dr. Bridger is a board member of Aquinox Pharmaceuticals.

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer.

The company's oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance.

X4's most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease, and is currently under investigation in multiple clinical trials in solid tumors.

X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.


Related Headlines